1-3 of 3
Christine Colby, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In Vivo and Ex Vivo T-Cell Depleted (TCD) NonmyeloablativeHaploidentical Stem Cell Transplantation (NSCT) for Hematologic Malignancy (HM).

Thomas R. Spitzer, MD, Steven L. McAfee, MD, Dey R. Bimalangshu, MD, Karen Ballen, MD, Eyal Attar, MD, Christine Colby, PharmD, Fred Preffer, PhD, Susan Saidman, PhD, Juanita Shaffer, David H. Sachs, MD, Megan Sykes, MD
Journal: Blood
Blood (2005) 106 (11): 5431.
https://doi.org/10.1182/blood.V106.11.5431.5431
Published: 2005
Journal Articles

Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).

Erica Linden, MD, Steven L. McAfee, MD, Bimalangshu R. Dey, MD, Karen Ballen, MD, Susan Saidman, PhD, Christine Colby, PharmD, Megan Sykes, MD, Thomas R. Spitzer, MD
Journal: Blood
Blood (2005) 106 (11): 3661.
https://doi.org/10.1182/blood.V106.11.3661.3661
Published: 2005
Journal Articles

Influence of First-Line Regimens on the Outcomes of High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma.

Bimalangshu R. Dey, MD, Benjamin Cox, A. Jo Chien, Martin Caron, Steven L. McAfee, MD, Christine Colby, PharmD, Thomas R. Spitzer, MD
Journal: Blood
Blood (2004) 104 (11): 931.
https://doi.org/10.1182/blood.V104.11.931.931
Published: 2004